Title: Methods and Compositions for Treating Keratin Hyperproliferative Disorders
Filed: Dec. 29, 2006
Lead Inventor: Roger Kaspar, TransDerm
The patent application, its abstract states, claims "a method for [treating] keratin hyperproliferation disorders such as corns, calluses, or keratosis pilaris by administering to a subject experiencing the disorder a therapeutically effective amount of an RNA sequence which inhibits expression of a gene encoding for a keratin selected from the group consisting of K6a, K6b, K16, K17, and combinations thereof."
The application specifically claims the use of an siRNA to achieve a therapeutic response.
Title: Specific GRP78 Expression-Inhibition RNAi Sequence, Medicine Thereof, and Method Thereof
Filed: July 17, 2008
Lead Inventor: Ann Joy Cheng, Sinorica
The invention, the patent application's abstract states, comprises the "RNAi sequence 5'-AAGGATGGTTAATGATGCTGAGAA-3', [which is] complementary to GRP78 [and] forms a special hairpin structure inside cancer cells to specifically and effectively inhibit GRP78 expression and then inhibit the canceration process, including the growth, migration, invasion, and metastasis of cancer."
Title: siRNA Targeting Phosphatases
Filed: Oct. 24, 2007
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to phosphatases."
Title: Small Internally Segmented Interfering RNA
Filed: March 23, 2007 PCT Filed: March 23, 2007
Lead Inventor: Jesper Wengel, RiboTask
The invention is "directed to pharmaceutical and therapeutic compositions which comprise RNA complexes comprising an antisense strand and a discontinued passenger strand capable of regulating gene expression," the patent application's abstract states. "The use of a discontinued passenger strand reduces off-target effects of the RNA complexes and also has other advantages."